American Renal Associates Holdings Inc (NYSE:ARA) has earned a consensus recommendation of “Buy” from the six brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $22.00.

Several research firms recently commented on ARA. ValuEngine cut American Renal Associates from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Zacks Investment Research cut American Renal Associates from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. SunTrust Banks reiterated a “buy” rating and set a $25.00 price target on shares of American Renal Associates in a research report on Thursday, August 9th. Leerink Swann upgraded American Renal Associates from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $22.00 to $26.00 in a research report on Thursday, August 23rd. Finally, Goldman Sachs Group started coverage on American Renal Associates in a research report on Thursday, July 19th. They set a “neutral” rating and a $16.00 price target on the stock.

Several hedge funds have recently modified their holdings of ARA. OppenheimerFunds Inc. acquired a new position in shares of American Renal Associates during the 1st quarter valued at $5,270,000. Dimensional Fund Advisors LP increased its position in shares of American Renal Associates by 94.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 495,708 shares of the company’s stock valued at $7,818,000 after purchasing an additional 240,542 shares during the period. BlackRock Inc. increased its position in shares of American Renal Associates by 33.2% during the 2nd quarter. BlackRock Inc. now owns 816,103 shares of the company’s stock valued at $12,869,000 after purchasing an additional 203,211 shares during the period. JPMorgan Chase & Co. increased its position in shares of American Renal Associates by 34.0% during the 1st quarter. JPMorgan Chase & Co. now owns 754,951 shares of the company’s stock valued at $14,230,000 after purchasing an additional 191,589 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of American Renal Associates by 111.2% during the 2nd quarter. Renaissance Technologies LLC now owns 347,500 shares of the company’s stock valued at $5,480,000 after purchasing an additional 183,000 shares during the period. Institutional investors own 93.25% of the company’s stock.

ARA traded up $0.27 during trading hours on Friday, hitting $20.58. The company’s stock had a trading volume of 66,400 shares, compared to its average volume of 162,668. American Renal Associates has a fifty-two week low of $9.91 and a fifty-two week high of $24.07. The company has a debt-to-equity ratio of 5.30, a current ratio of 1.07 and a quick ratio of 1.04. The stock has a market cap of $651.28 million, a P/E ratio of 32.77, a P/E/G ratio of 3.55 and a beta of 2.46.

American Renal Associates (NYSE:ARA) last posted its earnings results on Tuesday, August 7th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.17 by $0.03. American Renal Associates had a positive return on equity of 19.60% and a negative net margin of 1.11%. The firm had revenue of $217.18 million for the quarter, compared to analysts’ expectations of $203.70 million. equities analysts anticipate that American Renal Associates will post 0.6 EPS for the current year.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Further Reading: Marijuana Stocks Investing Considerations

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.